Is Bicara Therapeutics Inc. (BCAX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 40.9% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 40.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.1% / 33% | 96.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 40.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.1% / 33% | 96.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -26.6% | |
| Return on Assets (ROA) | -18.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$75M |
| Free Cash Flow | -$75M |
| Total Debt | $738,000 |
| Debt-to-Equity | 0.5 |
| Current Ratio | 14.1 |
| Total Assets | $510M |
Price & Trading
| Last Close | $18.92 |
| 50-Day MA | $17.15 |
| 200-Day MA | $14.74 |
| Avg Volume | 499K |
|
52-Week Range
$7.80
| |
About Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Bicara Therapeutics Inc. (BCAX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Bicara Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Bicara Therapeutics Inc.'s debt ratio?
Bicara Therapeutics Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.1%.
What are Bicara Therapeutics Inc.'s key financial metrics?
Bicara Therapeutics Inc. has a market capitalization of $1.2B, trailing P/E ratio of 3.4. Return on equity stands at -26.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.